Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
Top Cited Papers
- 1 June 2003
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 361 (9375), 2099-2106
- https://doi.org/10.1016/s0140-6736(03)13718-x
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidenceBritish Journal of Cancer, 2002
- Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trialThe Lancet, 2002
- Randomized Controlled Trial of Single-Agent Paclitaxel Versus Cyclophosphamide, Doxorubicin, and Cisplatin in Patients With Recurrent Ovarian Cancer Who Responded to First-Line Platinum-Based RegimensJournal of Clinical Oncology, 2002
- Cancer burden in the year 2000. The global pictureEuropean Journal Of Cancer, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2000
- Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trialsBritish Journal of Cancer, 1998
- ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancerThe Lancet, 1998
- Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.Journal of Clinical Oncology, 1998
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996